Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 3:1
Drug Approvals
2
NMPA:1
PHILIPPINES:1
Drug Approvals
Reduced Glutathione for Injection
- Product Name
- 泰特
- Approval Number
- 国药准字HJ20181207
- Approval Date
- Jun 7, 2023
NMPA
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 3
1 (50.0%)Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.
Phase 3
Recruiting
- Conditions
- PneumoniaMyocardial Injury
- Interventions
- Drug: TAD® 600 mg/4 mL powder and solvent for solution for injectionDrug: Saline solution 0.9% of sodium chloride
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 178
- Registration Number
- NCT06296212
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Pisana, Pisa, PI, Italy
🇮🇹Fondazione Policlinico Universitario Campus Bio-Medico, Roma, RM, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, RM, Italy
News
No news found